Log in
ASX:ANR

Anatara Lifesciences Limited (ANR.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.20
MA: A$0.20▼
A$0.20
52-Week Range N/A
Volume3,950 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Anatara Lifesciences Limited engages in the research and development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans in Australia. Its lead product candidate includes Detach, a non-antibiotic therapy that prevents and treats diarrhea disease in piglets. The company is also developing bromelain formulations for gastrointestinal health in humans, as well as for piglets and poultry. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.48 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:ANR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.anataralifesciences.com
Phone61 7 3394 8202
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio7.19
Quick Ratio7.14

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash Flow2.33
Book ValueA$0.06 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ANR News and Ratings via Email

Sign-up to receive the latest news and ratings for ANR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Anatara Lifesciences Limited (ANR.AX) (ASX:ANR) Frequently Asked Questions

Who are some of Anatara Lifesciences Limited (ANR.AX)'s key competitors?

Some companies that are related to Anatara Lifesciences Limited (ANR.AX) include (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB), Almirall (LBTSF) and Amarantus BioScience (AMBS).
View all competitors.

What other stocks do shareholders of Anatara Lifesciences Limited (ANR.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anatara Lifesciences Limited (ANR.AX) investors own include Woodside Petroleum Ltd (WPL.AX) (WPL), Temple & Webster Group Ltd (TPW.AX) (TPW), Brompton Oil Split Corp. (OSP.TO) (OSP), Eagle Materials (EXP), BHP Group (BHP) and Ameriprise Financial (AMP).

Who are Anatara Lifesciences Limited (ANR.AX)'s key executives?

Anatara Lifesciences Limited (ANR.AX)'s management team includes the following people:
  • Mr. Steven Lydeamore CPA, M.B.A., MBA, CPA, Chief Exec. Officer
  • Dr. Michael L. West, Chief Operating Officer (Age 56, Pay $296.83k)
  • Jane Lowe, Managing Director of IR Department
  • Dr. Stephen Denaro BCom, GradDipApp CG, CA, MAICD, Company Sec.
  • Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management, Commercial Mang.

What is Anatara Lifesciences Limited (ANR.AX)'s stock symbol?

Anatara Lifesciences Limited (ANR.AX) trades on the ASX under the ticker symbol "ANR."

How big of a company is Anatara Lifesciences Limited (ANR.AX)?

Anatara Lifesciences Limited (ANR.AX) has a market capitalization of $0.00.

What is Anatara Lifesciences Limited (ANR.AX)'s official website?

The official website for Anatara Lifesciences Limited (ANR.AX) is www.anataralifesciences.com.

How can I contact Anatara Lifesciences Limited (ANR.AX)?

The company can be reached via phone at 61 7 3394 8202.

This page was last updated on 10/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.